• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    US Neuropsychiatric Disorders Treatment Market

    ID: MRFR/HC/18441-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    US Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others) and By End User (Hospitals, Clinics, Research Centre’s, Others) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Neuropsychiatric Disorders Treatment Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    US Neuropsychiatric Disorders Treatment Market Summary

    The US Neuropsychiatric Disorders Treatment market is poised for substantial growth, projected to reach 88.7 USD Billion by 2035.

    Key Market Trends & Highlights

    US Neuropsychiatric Disorders Treatment Key Trends and Highlights

    • The market valuation is expected to grow from 30.5 USD Billion in 2024 to 88.7 USD Billion by 2035.
    • The compound annual growth rate (CAGR) for the period from 2025 to 2035 is estimated at 10.19%.
    • This growth trajectory indicates a robust expansion in treatment options and patient access across the United States.
    • Growing adoption of innovative therapies due to increasing prevalence of neuropsychiatric disorders is a major market driver.

    Market Size & Forecast

    2024 Market Size 30.5 (USD Billion)
    2035 Market Size 88.7 (USD Billion)
    CAGR (2025-2035) 10.19%

    Major Players

    AstraZeneca, Roche, Johnson and Johnson, Sanofi, Merck, Otsuka Pharmaceutical, H Lundbeck, Pfizer, Alkermes, Bristol Myers Squibb, Acadia Pharmaceuticals, GlaxoSmithKline, AbbVie, Eli Lilly and Company, Neurocrine Biosciences

    US Neuropsychiatric Disorders Treatment Market Trends

    The US Neuropsychiatric Disorders Treatment Market is undergoing significant movement because of factors such as the increasing awareness of mental health and the growing population of people suffering from neuropsychiatric disorders. According to the National Institute of Mental Health, millions of people in America are suffering from issues related to mental health, which creates a need for effective treatment options. Especially during the COVID-19 pandemic, telemedicine became increasingly popular, enabling patients to receive mental healthcare through online consultations from home. This change not only reduces treatment barriers but also meets contemporary needs in terms of how healthcare is provided.

    There is room for the creation of new therapies, particularly in the fields of personalized medicine and digital therapeutics. With advancements in technology, incorporating mobile health applications and even wearable health devices into treatment regimens provides patients with more ways to manage their diseases. Furthermore, there does appear to be a growing willingness towards alternative therapies that utilize traditional medicine, such as holistic mindfulness and wellness programs. Most recently, there has been an observable increase in focus on collaborative care, where psychiatrists focus on working with primary care providers in order to optimize treatment.

    Market Segment Insights

    Neuropsychiatric Disorders Treatment Market Type Insights

    The US Neuropsychiatric Disorders Treatment Market has clearly delineated segments that cater to various types of disorders, underscoring the market's complexity and the tailored approach required for effective treatment. Among these, degenerative diseases represent a significant category, including ailments like Alzheimer's and Parkinson's disease, which primarily affect cognitive function and motor skills. The aging population in the United States plays a pivotal role in the growth of this segment, as it is characterized by higher incidences of these disorders.

    Neurotic disorders, encompassing anxiety and mood-related issues, are prevalent and reflect the rising stress levels in contemporary society, making them a crucial aspect of neuropsychiatric care. This segment illustrates the need for innovative therapeutic solutions as patients seek relief from symptoms that profoundly impact their daily lives. Moreover, psychosis, including schizophrenia and severe mood disturbances, holds a critical place in the market due to the complexity of treatment required and the societal implications of these conditions. The US has seen increased attention toward early intervention and comprehensive treatment plans for such disorders, highlighting their impact on both individuals and communities.

    Additionally, the category of "others" encompasses various miscellaneous disorders, reflecting the vast spectrum of neuropsychiatric conditions. These lesser-known disorders are often underrepresented yet require substantial resources to manage and treat effectively. Overall, the diversity within these segments illustrates the multifaceted nature of the US Neuropsychiatric Disorders Treatment Market, where different areas necessitate distinct approaches for diagnosis and management, paving the way for a more focused and efficient healthcare model that aligns with patient needs.

    Market growth in this domain is supported by ongoing research, the development of advanced treatment methodologies, and an increasing acknowledgment of mental health issues, all of which indicate a forward momentum in addressing neuropsychiatric disorders across the United States.

    Neuropsychiatric Disorders Treatment Market Application Insights

    The US Neuropsychiatric Disorders Treatment Market encompasses a diverse range of applications, notably including Shock Treatment, Drug Treatment, and others that contribute to addressing various neuropsychiatric conditions. Drug Treatment remains a crucial element, as it encompasses a wide array of medications tailored to manage symptoms associated with disorders such as depression, anxiety, and schizophrenia, making it a significant driver of both market growth and patient outcomes. Shock Treatment often serves as a vital intervention for severe cases, particularly in treatment-resistant depression, making it an important option within the market.

    Furthermore, the Others segment includes emerging therapies and alternative treatments such as cognitive-behavioral therapy (CBT) and mindfulness, which are gaining traction due to rising patient demand for holistic approaches. The integration of advanced technologies, such as digital therapeutics, is also influencing treatment strategies in these applications. Overall, the emphasis on personalized treatment approaches is shaping the landscape of the US Neuropsychiatric Disorders Treatment Market, addressing the diverse needs of patients while contributing to ongoing innovation in the industry.

    Neuropsychiatric Disorders Treatment Market End User Insights

    The US Neuropsychiatric Disorders Treatment Market, particularly within the End User segment, reveals a structured landscape comprising various key settings, notably hospitals, clinics, research centers, and others. Hospitals play a crucial role, serving as primary facilities for acute care and specialized treatments, leading to a significant proportion of market engagement. Clinics, often more accessible, offer ongoing care and management for chronic neuropsychiatric conditions, which fosters continuity of treatment for patients. Research centers contribute significantly to advancements in understanding neuropsychiatric disorders and developing innovative therapeutic solutions, thus driving market growth through their commitment to research and clinical trials.

    Additionally, other platforms, such as outpatient services and rehabilitation facilities, serve important functions in patient recovery and management. The overall segmentation within the US Neuropsychiatric Disorders Treatment Market underscores a diverse range of treatment environments that cater to the unique needs of affected individuals, enhancing access and improving outcomes in mental health care. This varied approach not only supports the evolving nature of treatments but also highlights the importance of integrating multiple care settings to address the complexities associated with neuropsychiatric disorders.

    Get more detailed insights about US Neuropsychiatric Disorders Treatment Market Research Report - Forecast to 2035

    Key Players and Competitive Insights

    The US Neuropsychiatric Disorders Treatment Market boasts a diverse and competitive landscape characterized by rapid advancements in research and therapeutic options aimed at addressing a wide array of mental health conditions. The increasing prevalence of neuropsychiatric disorders, coupled with rising awareness and reduced stigma surrounding mental health, has driven extensive investment in drug development and innovative treatment mechanisms. In this market, various pharmaceutical companies vie for leadership through novel therapeutics, improved patient experiences, and strategic collaborations.

    Competitive strengths such as research capabilities, market access strategies, and regulatory compliance play pivotal roles in determining the success of organizations in this sector, leading to a dynamic and evolving competitive landscape. AstraZeneca has solidified its position as a significant player in the US Neuropsychiatric Disorders Treatment Market by leveraging its strong research and development capabilities, which have led to the introduction of innovative therapies. The company maintains a robust pipeline targeting various conditions, capitalizing on strategic alliances and partnerships that enhance its market presence.

    AstraZeneca benefits from its established brand recognition and a strong distribution network within the United States, facilitating effective communication and interaction with healthcare professionals and patients. The combination of AstraZeneca’s commitment to addressing unmet medical needs and capabilities in navigating regulatory landscapes contributes to its strengths in effectively competing in this specialized market. Roche has established itself as a formidable entity in the US Neuropsychiatric Disorders Treatment Market through a diverse portfolio that includes key products and services targeting neuropsychiatric conditions.

    The company's strong emphasis on research and development is coupled with a history of successful mergers and acquisitions, allowing it to expand its therapeutic offerings while enhancing its market presence. Roche's strengths lie in its comprehensive understanding of patient needs, its commitment to personalized medicine, and its extensive engagement with healthcare providers. By investing in both innovative treatment options and continued research into the underlying mechanisms of neuropsychiatric disorders, Roche positions itself strategically within the market, tapping into emerging opportunities while addressing existing challenges.

    Key Companies in the US Neuropsychiatric Disorders Treatment Market market include

    Industry Developments

    The US Neuropsychiatric Disorders Treatment Market has seen significant developments recently, particularly in relation to major pharmaceutical companies involved. Notably, AstraZeneca and Merck have reported advancements in their product pipelines, focusing on innovative therapies for depression and anxiety disorders as of October 2023. Roche has also expanded its offerings, emphasizing personalized medicine approaches to improve patient outcomes in neuropsychiatric conditions. In terms of mergers and acquisitions, Johnson & Johnson announced an acquisition of a smaller biotech company specializing in novel antipsychotic drugs in September 2023, further consolidating its presence in this sector.

    Meanwhile, both Otsuka Pharmaceutical and H Lundbeck have been actively engaging in collaborations to enhance their research capabilities, which are aimed at developing next-generation therapeutics. The growth in market valuation for companies like Eli Lilly and Company and AbbVie has been substantial as these firms continue to innovate and launch new treatments, positively impacting their competitive positions. In the last two years, increased awareness around mental health and broader access to treatment options have contributed to a surge in demand, influencing overall market dynamics within the US.

    Market Segmentation

    US Neuropsychiatric Disorders Treatment Market Type Outlook

    • Degenerative Diseases
    • Neurotic Disorders
    • Psychosis
    • Others

    US Neuropsychiatric Disorders Treatment Market End User Outlook

    • Hospitals
    • Clinics
    • Research Centre’s
    • Others

    US Neuropsychiatric Disorders Treatment Market Application Outlook

    • Shock Treatment
    • Drug Treatment
    • Others

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 27.64(USD Billion)
    Market Size 2024 30.5(USD Billion)
    Market Size 2035 88.7(USD Billion)
    Compound Annual Growth Rate (CAGR) 10.191% (2025 - 2035)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2019 - 2024
    Market Forecast Units USD Billion
    Key Companies Profiled AstraZeneca, Roche, Johnson and Johnson, Sanofi, Merck, Otsuka Pharmaceutical, H Lundbeck, Pfizer, Alkermes, Bristol Myers Squibb, Acadia Pharmaceuticals, GlaxoSmithKline, AbbVie, Eli Lilly and Company, Neurocrine Biosciences
    Segments Covered Type, Application, End User
    Key Market Opportunities Telehealth expansion for treatment access, Personalized medicine and genomics integration, Growing awareness and education initiatives, Innovative digital therapeutics development, Long-term care facility partnerships
    Key Market Dynamics Rising prevalence of mental disorders, Increased focus on personalized medicine, Advancements in neurotherapeutics, Growing acceptance of telepsychiatry, Expanding pipeline of innovative treatments
    Countries Covered US

    FAQs

    What is the expected market size of the US Neuropsychiatric Disorders Treatment Market in 2024?

    The US Neuropsychiatric Disorders Treatment Market is expected to be valued at 30.5 USD billion in 2024.

    What is the projected market size of the US Neuropsychiatric Disorders Treatment Market by 2035?

    By 2035, the market is anticipated to reach a valuation of 88.7 USD billion.

    What is the expected compound annual growth rate (CAGR) for the US Neuropsychiatric Disorders Treatment Market from 2025 to 2035?

    The expected CAGR for the market from 2025 to 2035 is 10.191%.

    Which segment is projected to dominate the US Neuropsychiatric Disorders Treatment Market in 2024?

    Degenerative Diseases are projected to dominate the market, valued at 12.3 USD billion in 2024.

    What is the expected growth of the Neurotic Disorders segment in the US Neuropsychiatric Disorders Treatment Market by 2035?

    The Neurotic Disorders segment is expected to grow to 26.4 USD billion by 2035.

    Who are the key players in the US Neuropsychiatric Disorders Treatment Market?

    Major players include AstraZeneca, Roche, Johnson and Johnson, Sanofi, and Merck.

    How much is the Psychosis segment projected to be valued in 2035?

    The Psychosis segment is projected to reach a value of 16.8 USD billion by 2035.

    What challenges does the US Neuropsychiatric Disorders Treatment Market currently face?

    The market faces challenges such as high costs of treatment and limited access to care.

    What are the growth drivers for the US Neuropsychiatric Disorders Treatment Market?

    Key growth drivers include increasing prevalence of neuropsychiatric disorders and advancements in treatment options.

    What expected market size is there for 'Others' category in the US Neuropsychiatric Disorders Treatment Market in 2024?

    The 'Others' category is expected to be valued at 4.2 USD billion in 2024.

    What is the projected market size of the US Neuropsychiatric Disorders Treatment Market in 2024?

    The US Neuropsychiatric Disorders Treatment Market is expected to be valued at 30.5 USD billion in 2024.

    What will be the estimated market size by 2035?

    By 2035, the market is anticipated to reach a value of 88.7 USD billion.

    What is the expected compound annual growth rate (CAGR) for the market during the forecast period?

    The expected CAGR for the US Neuropsychiatric Disorders Treatment Market from 2025 to 2035 is 10.191%.

    Which segment dominates the market in terms of revenue in 2024?

    In 2024, Neurotic Disorders is the dominant segment valued at 10.2 USD billion.

    What is the market size for Psychosis treatments in 2024?

    The market size for Psychosis treatments is projected to be 6.3 USD billion in 2024.

    Which are the major players in the US Neuropsychiatric Disorders Treatment Market?

    Key players in the market include Novartis AG, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

    What is the expected market value for Degenerative Diseases treatments by 2035?

    The market value for Degenerative Diseases treatments is expected to grow to 26.1 USD billion by 2035.

    How much is the Others segment valued at in 2035?

    The Others segment is anticipated to be valued at 13.0 USD billion in 2035.

    What is the revenue expectation for Neurotic Disorders by 2035?

    The revenue for Neurotic Disorders is expected to reach 30.8 USD billion by 2035.

    What drives the growth of the US Neuropsychiatric Disorders Treatment Market?

    Key growth drivers include increasing prevalence of neuropsychiatric disorders and advancements in treatment platforms.

    US Neuropsychiatric Disorders Treatment Market Research Report - Forecast to 2035 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials